Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, outlines the preliminary results of a Phase II study investigating camidanlumab tesirine (Cami) as a treatment for relapsed/refractory classical Hodgkin lymphoma (cHL). This novel pyrrolobenzodiazepine-based antibody-drug conjugate demonstrated encouraging anti-tumor activity and an acceptable safety profile. More data collection is underway as patients continue to be enrolled. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Research funding: Bristol Myers Squibb, Seattle Genetics, ADC Therapeutics, Affimed, Trillium, AI Therapeutics, Regeneron